Hello guest, Register  |  Sign In
Virologica Sinica, 23 (2) : 137-145, 2008
Review
Anti-Hepatitis B Virus Drugs in Clinical and Preclinical Development
1. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2. Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
 Correspondence:
(243.09KB)  
Abstract
Up to date, there are two types of drugs approved to treat hepatitis B: interferons and nucleos (t) ide analogues. However, the therapies are limited in the clinical context because of the negative side effects of interferon-α and the development of substantial viral resistance to nucleos (t) idic inhibitors. Therefore, new drugs with novel structures and mechanisms are needed. In this article, the drugs approved by FDA or the European Commission for treating chronic hepatitis B virus infection, as well as those under clinical trials, and several compounds in preclinical studies are reviewed. Additionally, some potential targets and strategies to combat chronic hepatitis B virus infection are discussed.
  Published online: 25 Apr 2008
Home |  Resources |  About Us |  Support |  Contact Us |  Privacy |  Powered by CanSpeed | 
Copyright © 2015 Virologica Sinica. All rights reserved